A phase I study of the antimetabolite (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731) administered as a twice-weekly infusion.

Burtness, B; Belker, M; Stoltz, M; Peccerillo, K M; Lamb, L A; Chmael, S E; McKeon, A; Clark, M B; Winship, J; Marsh, J C; Pizzorno, G; DeVita, V T

Burtness, B; Belker, M; Stoltz, M; Peccerillo, K M; Lamb, L A; Chmael, S E; McKeon, A; Clark, M B; Winship, J; Marsh, J C; Pizzorno, G; DeVita, V T.

Affiliation

Burtness B; Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520-8032, USA.

Cancer J ; 6(5): 309-15, 2000.

Article de En | MEDLINE | ID: mdl-11079170

Sujet(s)

Recherche sur Google

Ajouter à My VHL

Imprimer

XML

PubMed Links

Collection: 01-internacional Base de données: MEDLINE Sujet principal: Désoxycytidine / Tumeurs / Antinéoplasiques Type d'étude: Prognostic_studies Limites: Adult / Aged / Female / Humans / Male / Middle aged Langue: En Journal: Cancer J Sujet du journal: NEOPLASIAS Année: 2000 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: États-Unis d'Amérique

Recherche sur Google

Ajouter à My VHL

Imprimer

XML

PubMed Links